MAIA Biotechnology, Inc.

MAIA NYSE SEC CIK 1878313
Follow MAIA Biotechnology Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$7.2M +19.4% vs same quarter last year
EPS, diluted −$0.12 +55.6% vs same quarter last year
Operating cash flow −$6.3M −81% vs same quarter last year
Operating income −$8M +14.3% vs same quarter last year
Net income by quarter
−$3.6M
−$4.5M
−$5.3M
−$8.9M
−$3.6M
−$6.4M
−$7.9M
−$7.2M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income6 fiscal years
  • Revenue
  • Net income
−$30M−$20M−$10M$0FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25-−$22.4M
FY24$0−$23.3M
FY23$0−$19.8M
FY22$0−$15.8M
FY21-−$12.6M
FY20--